Navigation Links
Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
Date:1/15/2008

nts in a two-stage trial design. Patients with HER2-positive metastatic disease and no prior trastuzumab treatment except as adjuvant therapy (with the last dose more than 12 months prior to study entry) are eligible to participate in the trial. Alvespimycin will be administered intravenously on a one-hour weekly infusion schedule of 80 mg/m2 for three weeks out of four weeks in repeated cycles.

Kosan is also testing alvespimycin delivered orally in a Phase 1 dose escalation trial exploring different schedules.

Promising Antitumor Activity Shown in Phase 1

In September, at the 2007 ASCO Breast Cancer Symposium, Kosan reported that alvespimycin demonstrated promising antitumor activity and tolerability in combination with trastuzumab in a Phase 1 trial of patients with refractory HER2-positive metastatic breast cancer, and in patients with refractory ovarian cancer who were progressing on standard chemotherapy. Of the 27 heavily-pretreated patients enrolled in the Phase 1 trial, 24 patients had HER2-positive metastatic breast cancer and 3 patients had ovarian cancer (HER2 status unknown). Clinical benefit was observed in 42% of patients (8 of 19 evaluable) with HER2-positive metastatic breast cancer. Of the 3 patients with ovarian cancer, 1 patient (13 prior regimens) who was on study for more than 16 months had a near complete resolution of ascites and left pleural effusion, and an 83% decrease in CA125. Toxicities in this Phase 1 trial were mainly Grade 1 and 2 (diarrhea, fatigue, headache, arthralgia, nausea) with 80 mg/m2 established as the recommended Phase 2 dose for weekly intravenous administration. Kosan is currently enrolling a Phase 1 trial to investigate alvespimycin plus trastuzumab and paclitaxel to establish the initial safety profile and pharmacokinetics of this triplet regimen and to lay the groundwork for a potential larger Phase 2/3 trial.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
2. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
3. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
4. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
5. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
6. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
7. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
8. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
9. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
10. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
11. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Colo. , Nov. 25, 2014 /PRNewswire/ ... ) today announced that its Chief Executive ... at the following upcoming conferences.  The public ... through webcasts on the Array BioPharma website:  ... December 3, 2014Time:1:30 p.m.  Eastern Time Location: ...
(Date:11/26/2014)... Nov. 25, 2014 Immune Pharmaceuticals Inc. ... stage biopharmaceutical company that engages in the development ... of inflammatory diseases and cancer, today announced the ... of 3,450,000 units, with each unit consisting of ... value $0.0001 per share, and one warrant to ...
(Date:11/24/2014)...  CryoLife, Inc. (NYSE: CRY ), a leading ... vascular surgery, announced today that it will participate in the ... Wednesday, December 3, 2014 at The New York Palace Hotel ... A live webcast of the Company,s presentation is scheduled to ... of the company by Pat Mackin , President and ...
Breaking Medicine Technology:Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3
(Date:11/26/2014)... Dr. Parsa Mohebi is giving prospective ... With Parsa Mohebi Hair Restoration’s new winter special, patients ... FUE procedure, making it that much easier to get ... Unit Extraction”—is an advanced variety of hair restoration surgery ... Transplantation (FUT). FUE, unlike FUT, does not leave a ...
(Date:11/26/2014)... 27, 2014 Recently, Locks-Magnetic.com, a Chinese ... collection of magnetic locks on the Internet. It also ... until December. , As a leading company in ... for worldwide customers to buy high quality locks. It ... it provides locks that are not only useful but ...
(Date:11/26/2014)... (PRWEB) November 27, 2014 Boxing Day ... and tradesmen would receive gifts, known as a "Christmas ... Wikipedia ) , With the coming of Boxing Day, ... Tbdress.com is smart before every business opportunity, and it ... ”, offering a site-wide promotion for its global customers. ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Pharmaceutical ... humidity, and pressure levels during manufacturing and research ... and air conditioning) systems play a key role. ... microorganisms or bio-contaminants, while humidity can affect the ... The use of HVAC systems helps to address ...
(Date:11/26/2014)... Dallas, Texas (PRWEB) November 26, 2014 ... surgeon and Distinguished Teaching Professor in the ... Center, recently discussed facial fat compartments, fat grafting, ... Surgery, The Meeting," an annual conference held by ... importance and intricacies of this underlying facial structure ...
Breaking Medicine News(10 mins):Health News:FUE Special at Parsa Mohebi Hair Restoration This Holiday Season 2Health News:Fresh Products Launched by Famous Company Lock-Magnetic.com 2Health News:Tbdress.com: Best Boxing Day Sales For Ladies Worldwide 2Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 5Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 2Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 3
... ... procedures, raising the bar for minimally invasive surgery. , ... Singapore (Vocus) May 12, 2010 -- Gynaecologists at ... new heights with the introduction of a specially designed port that allows surgeons to ...
... ... , ... Butch Patrick was driving on a rainy evening in Beverly Hills he found it difficult to ... He even had difficulty reading the cue cards,and in spite of his reading glasses and ...
... researchers say , TUESDAY, May 11 (HealthDay News) -- Adults ... problems, which can affect their ability to cope with daily ... of community resources, and socializing, a new study finds. , ... ages 19 to 55, and a control group of 47 ...
... Health Sciences Center announced today that it has received ... & Melinda Gates Foundation. The grant will support ... K. Joshi, assistant professor in the Department of Microbiology ... Strategy for Immune Intervention." Joshi,s project is one ...
... Many don,t know the facts and don,t recognize the symptoms, U.S. ... online survey of U.S. women finds only about one in four ... symptoms of stroke. , This is important because researchers say ... at the hospital after a stroke, and researchers think lack of ...
... Bloomberg School of Public Health announced today that it ... the Bill & Melinda Gates Foundation. The grant will ... Jason Rasgon, PhD, an assistant professor with the Johns ... an evolution-proof pesticide for eliminating mosquitoes that transmit malaria ...
Cached Medicine News:Health News:Singapore's Gynaecologists Break New Grounds 2Health News:Singapore's Gynaecologists Break New Grounds 3Health News:Singapore's Gynaecologists Break New Grounds 4Health News:Little Munster Has Cataract According to Dr. Rajesh Khanna 2Health News:Sickle Cell Disease Tied to Cognitive Difficulties 2Health News:OUHSC receives $100,000 Grand Challenges Explorations grant for innovative global health research 2Health News:Women Often Miss Signs of Stroke 2Health News:Bloomberg School receives $100K Grand Challenges Explorations grant 2
Maltzman-Fenzl lens manipulator, V shaped tip, straight. Also available in titanium....
0.3 mm diameter hemi-ball tip....
Vaulted shank with guard....
... individually adjusted for perfect focus where it's ... paper. This, along with Keeler's wide angle ... whatever the patient's pupil size, you will ... view. Lithium-ion technology provides a longer life ...
Medicine Products: